e-Therapeutics plc Director Dealing (3181Q)
October 26 2021 - 7:55AM
UK Regulatory
TIDMETX
RNS Number : 3181Q
e-Therapeutics plc
26 October 2021
e-therapeutics plc
("e-therapeutics" or the "Company")
Director Dealing
Oxford, UK, 26 October 2021 - e-therapeutics plc (AIM: ETX;
OTCQX: ETXPF), a specialist in computational drug discovery with a
focus on developing RNA interference ("RNAi") therapeutics,
announces the following dealing in the Company's ordinary shares of
0.1 pence each ("Ordinary Shares").
Earlier today, Mr Ali Mortazavi, the Company's Chief Executive
Officer, purchased 275,000 Ordinary Shares at a price of 36.5 pence
each.
Following the transaction, Mr Mortazavi is benefically
interested in 50,941,666 Ordinary Shares, representing 9.9% of the
Company's total issued share capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further details:
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Ali Mortazavi
-------------------------- -------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------
a) Position/status Chief Executive Officer
-------------------------- -------------------------------------------
b) Initial notification/ Initial notification
Amendment
-------------------------- -------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name e-therapeutics plc
-------------------------- -------------------------------------------
b) LEI 21380049RHSSJXWKYT18
-------------------------- -------------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
-----------------------------------------------------------------------
a) Description of the Ordinary Shares of 0.1 pence
financial instrument,
type of instrument ISIN: GB00B2823H99
Identification code
-------------------------- -------------------------------------------
b) Nature of the transaction Purchase of shares
-------------------------- -------------------------------------------
c) Price(s) and volume(s) 275,000 ordinary shares at a price of 36.5
pence per share
-------------------------- -------------------------------------------
d) Aggregated information 275,000 ordinary shares
- Aggregated volume 36.5 pence per share
- Price Aggregated value: GBP100,375
-------------------------- -------------------------------------------
e) Date of the transaction 26 October 2021
-------------------------- -------------------------------------------
f) Place of the transaction AIM
-------------------------- -------------------------------------------
Enquiries :
e-therapeutics plc Tel: +44 (0)1993 883
125
Ali Mortazavi, CEO www.etherapeutics.co.uk
Karl Keegan, CFO
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Broker
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Rob Rees (Corporate
Broking)
About e-therapeutics plc
e-therapeutics plc is an Oxford, UK-based company integrating
computational power and biology to accelerate the discovery of
life-transforming medicines. The Company has developed and
validated a powerful, disease and modality agnostic computational
approach to drug discovery, leveraging its industry-leading
expertise in network biology to fully capture and interrogate human
disease complexity.
The Company's multi-disciplinary team builds computational
models of biological functions to transform the search for new
medicines, interventions, mechanisms and genetic support. Its
biology-led in silico laboratory enables rapid hypothesis
generation and phenotypic screening of millions of compounds
leading to 100-1000x higher hit rates in the wet lab and successful
mode of action elucidation. Novel targets can also be identified,
prioritised and assessed. Harnessing internal target gene
discoveries, e-therapeutics is currently building an in-house
pipeline of RNAi based medicines, using its proprietary
GalNAc-siRNA technology.
e-therapeutics has deployed and validated its disease-agnostic
computational drug discovery platform both in house and with
partners, including Novo Nordisk, Galapagos NV and a US-based, top
5 pharmaceutical company.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFLFEFISLRFIL
(END) Dow Jones Newswires
October 26, 2021 08:55 ET (12:55 GMT)
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Mar 2024 to Apr 2024
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Apr 2023 to Apr 2024
